| Recruiting | A Study to Assess the Safety of ARGX-124 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2026-01-26 |
| Recruiting | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Particip AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG | Phase 2 | 2025-12-19 |
| Recruiting | A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Admi Spinal Muscular Atrophy (SMA) | Phase 2 | 2025-12-19 |
| Recruiting | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens i Myasthenia Gravis, MG, gMG | — | 2025-12-19 |
| Recruiting | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thro Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP | Phase 2 / Phase 3 | 2025-10-20 |
| Recruiting | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 3 | 2025-09-16 |
| Recruiting | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | 2025-08-22 |
| Recruiting | Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | — | 2025-08-11 |
| Recruiting | A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthe New Onset Generalized Myasthenia Gravis (gMG) | Phase 4 | 2025-04-17 |
| Recruiting | A Study to Assess the Safety of ARGX-213 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2025-04-11 |
| Active Not Recruiting | A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome Primary Sjogrens Disease | Phase 3 | 2025-01-15 |
| Completed | A Study to Assess the Safety of ARGX-109 in Healthy Volunteers Healthy Volunteer | Phase 1 | 2025-01-14 |
| Recruiting | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropa Multifocal Motor Neuropathy (MMN), MMN | Phase 3 | 2024-12-18 |
| Completed | A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC Chronic Inflammatory Demyelinating Polyneuropathy | Phase 4 | 2024-12-10 |
| Recruiting | A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis Systemic Sclerosis (SSc) | Phase 2 | 2024-11-11 |
| Recruiting | A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa Myasthenia Gravis | — | 2024-11-04 |
| Active Not Recruiting | A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis | Phase 2 | 2024-10-23 |
| Recruiting | A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombo Primary Immune Thrombocytopenia (ITP) | Phase 3 | 2024-10-18 |
| Recruiting | A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Congenital Myasthenic Syndrome, CMS | Phase 1 | 2024-09-24 |
| Active Not Recruiting | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis Myasthenia Gravis, Ocular | Phase 3 | 2024-09-18 |
| Recruiting | A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney T Antibody-mediated Rejection | Phase 2 | 2024-08-30 |
| Active Not Recruiting | A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis Dermatomyositis, Myositis | Phase 2 | 2024-08-20 |
| Recruiting | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myastheni Generalized Myasthenia Gravis | Phase 2 / Phase 3 | 2024-06-28 |
| Active Not Recruiting | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized | Phase 3 | 2024-04-16 |
| Terminated | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. Thyroid Eye Disease | Phase 3 | 2024-03-28 |
| Terminated | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease Thyroid Eye Disease | Phase 3 | 2024-03-27 |
| Active Not Recruiting | ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function Delayed Graft Function | Phase 2 | 2024-02-17 |
| Recruiting | A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, M Congenital Myasthenic Syndrome | — | 2024-02-13 |
| Recruiting | A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgart Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | — | 2023-11-30 |
| Completed | Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syn Primary Sjögren's Syndrome | Phase 2 | 2023-11-29 |
| Active Not Recruiting | A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy Multifocal Motor Neuropathy | — | 2023-11-29 |
| Enrolling By Invitation | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults Wi Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis | Phase 3 | 2023-09-12 |
| Completed | A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod Renal Impairment | Phase 1 | 2023-07-17 |
| Terminated | Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome | Phase 2 | 2023-06-20 |
| Completed | A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) Primary Sjögren's Syndrome | Phase 2 | 2023-04-04 |
| Terminated | A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult P Bullous Pemphigoid | Phase 3 | 2023-03-22 |
| Completed | A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syri Bioequivalence | Phase 1 | 2023-03-13 |
| Completed | A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-0 Lupus Nephritis | Phase 2 | 2023-02-21 |
| Completed | A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and M Healthy Volunteers | Phase 1 | 2023-02-21 |
| Terminated | A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephrop Membranous Nephropathy | Phase 2 | 2023-02-20 |
| Active Not Recruiting | A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokin Multifocal Motor Neuropathy (MMN) | Phase 2 | 2023-01-18 |
| Active Not Recruiting | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiop Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis | Phase 2 / Phase 3 | 2022-10-12 |
| Completed | Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS Postural Orthostatic Tachycardia Syndrome | Phase 2 | 2022-09-23 |
| Enrolling By Invitation | Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subc Generalized Myasthenia Gravis, gMG | Phase 2 / Phase 3 | 2022-08-18 |
| Completed | A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid Bullous Pemphigoid | Phase 2 / Phase 3 | 2022-06-09 |
| Completed | A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Multifocal Motor Neuropathy | Phase 2 | 2022-03-31 |
| Completed | An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Pa Generalized Myasthenia Gravis, MG - Myasthenia Gravis, gMG | Phase 3 | 2021-12-16 |
| Active Not Recruiting | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With P Primary Immune Thrombocytopenia | Phase 3 | 2021-11-17 |
| Completed | Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV Healthy Volunteers | Phase 1 | 2021-11-17 |
| Recruiting | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Ch Generalized Myasthenia Gravis | Phase 2 / Phase 3 | 2021-10-26 |
| Terminated | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in A Pemphigus Vulgaris, Pemphigus Foliaceus | Phase 3 | 2021-07-15 |
| Completed | Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patien Generalized Myasthenia Gravis | Phase 3 | 2021-04-26 |
| Completed | Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared Generalized Myasthenia Gravis | Phase 3 | 2021-02-05 |
| Completed | A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary I Primary Immune Thrombocytopenia | Phase 3 | 2020-12-16 |
| Completed | A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus Vulgaris, Pemphigus Foliaceus | Phase 3 | 2020-12-01 |
| Active Not Recruiting | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults Wi Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 2 | 2020-09-18 |
| Completed | A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Healthy Volunteers | Phase 1 | 2020-08-18 |
| Completed | SAD and MAD Study With IV and SC Doses of ARGX-117 Healthy Volunteers | Phase 1 | 2020-08-03 |
| Withdrawn | A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopen Primary Immune Thrombocytopenia (ITP) | Phase 3 | 2020-06-29 |
| Completed | A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thro Primary Immune Thrombocytopenia | Phase 3 | 2020-06-02 |
| Completed | A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 2 | 2020-04-15 |
| Completed | A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopen Primary Immune Thrombocytopenia | Phase 3 | 2019-12-16 |
| Completed | Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects Healthy Volunteers | Phase 1 | 2019-07-17 |
| Completed | A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Wea Generalized Myasthenia Gravis | Phase 3 | 2019-03-01 |
| Completed | An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakne Generalized Myasthenia Gravis | Phase 3 | 2018-08-22 |
| Completed | A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus Pemphigus Vulgaris, Pemphigus Foliaceus | Phase 2 | 2017-10-18 |
| Completed | A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Health Bioavailability Study | Phase 1 | 2017-10-11 |
| Completed | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP Primary Immune Thrombocytopenia | Phase 2 | 2017-03-13 |
| Completed | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Myasthenia Gravis | Phase 2 | 2016-12-30 |
| Completed | IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2015-09-09 |
| Completed | A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) Cancer | Phase 1 | 2015-02-01 |
| Completed | A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. Cancer | Phase 1 | 2014-01-01 |
| Available | Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), CIDP | — | — |